COVID-19 enfeksiyonu geçiren hastalarda baş ağrısı özellikleri ve risk faktörleri
Yükleniyor...
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Baş ağrısı COVID-19 ile ilişkili en yaygın nörolojik semptomdur. COVID-19 enfeksiyonu için baş ağrısının tanısal ipuçlarını ortaya koymayı ve pandemi sırasında primer baş ağrılarının seyrini araştırmayı amaçladık.
Yöntem: Çalışmamız Aralık 2020-Haziran 2021 tarihleri arasında hastanemizde yatırılarak takip ve tedavi gören, güncel Sağlık Bakanlığı COVID-19 rehberi temel alınarak COVID-19 tanısı alan olgular teletıp yöntemi ile aranarak gerçekleştirildi. Hasta grubu olarak 18-95 yaş arası COVID-19’a yakalanmış olup hastalığı sırasında baş ağrısı olan 102 hasta, kontrol grubu olarak 18-95 yaş arası COVID-19’a yakalanan ve hastalığı sırasında baş ağrısı olmayan 96 hasta çalışmaya dahil edildi. Veri toplama için standartlaştırılmış bir anket formu kullanılmıştır.
Bulgular: Çalışmamızda 198 olgunun (Hasta:102, Kontrol:96) 102’si (%51,5) erkek ve 96’sı (%48,5) kadındı. Baş ağrısı grubunun yaş ortalaması 56,48±14,73, kontrol grubunun yaş ortalaması ise 57,81±15.89 olduğu saptandı. Baş ağrısı ve kontrol grubu arasında cinsiyet ve yaş açısından anlamlı farklılık saptanmadı (p>0,05). Olguların 102’sinde (%51,5) kilo kaybı, 85’sinde (%42,9) tat kaybı, 84’te (%42,4) koku kaybı saptandı. Tat kaybı derecesine bakıldığında hastaların 50’sinde (%25,3) tam tat kaybı mevcutken 113’ünde (%57,1) tat kaybı yoktu. Koku kaybı derecesine bakıldığında,
v
hastaların 50’sinde (%25,3) tam koku kaybı varken, 114’ünde(%57,6) koku kaybı yoktu. Baş ağrısı grubunda kilo kaybı, tat kaybı, koku kaybı, koku kaybı derecesi ve enfeksiyon şiddetinin ciddiyeti anlamlı olarak yüksek saptandı (p<0,05). Gruplar arasında tat kaybı derecesi açısından anlamlı farklılık saptanmadı (p>0,05). Çalışmamızda baş ağrısı grubunda kilo kaybı ve cinsiyetin bağımsız risk faktörü olduğu saptandı. Koku kaybı olan bireylerde kilo kaybı, cinsiyet ve tat kaybının bağımsız değişken olduğu saptandı. Laboratuvar değerlerinden baş ağrısı grubunda D-dimer ve fibrinojen anlamlı olarak yüksek saptandı (p<0,05). Ek hastalıklar açısından incelendiğinde baş ağrısı grubunda solunum patolojisi olan hasta sayısı anlamlı olarak yüksek saptandı (p<0,05). Baş ağrısı grubunda ek baş ağrısı sıklığı ve COVID-19 ile baş ağrısında artış anlamlı olarak yüksek saptandı (p<0,05). Lokalizasyonuna göre hastaların 23’ünde (%22,5) frontal bölgede, 33’ünde (%32,4) temporal bölgede, 17’ sinde (%16,7) parietal bölgede, 58’inde (%56,9) oksipital bölgede baş ağrısı mevcuttu. Hastaların 23’ünde (%22,5) yaygın, 10’unda (%9,8) bilateral, 9’unda (%8,8) tek taraflı bir baş ağrısı mevcuttu. Baş ağrısı özelliğine baktığımız zaman 74’ünde(%72,5) zonklayıcı, 22’sinde(%21,6) sıkıştırıcı karakterdeydi. Hastalarımızın baş ağrısı şiddeti değerlendirilmesinde kullanılan NRS (Nümerik Derecelendirme Ölçeği) skoru ortancası 7 (IQR 3) olarak saplandı. Hastalarımızın 76’sında (%74,5) baş ağrısı ile ateş arasında ilişki yoktu. 70’inde (%68,6) baş ağrısı ile öksürük arasında ilişki yoktu. 86’sında (%84,3) bulantı kusma eşlik etmiyordu. 83’ün de (%81,4) baş ağrılarının olduğu dönem de ışığa ve sese karşı hassasiyetleri mevcut değildi. 79’u (%77,5) ağrı kesiciye orta düzeyde yanıt vermişti. 57’sinde (%55,9) baş ağrısının fiziksel aktivite ile değişmediği tespit edildi. Sonuç: Baş ağrısı COVID-19’un çok yaygın bir semptomudur. COVID-19 enfeksiyonlu hastaları takip eden klinisyenler bu hastalarda görülebilecek baş ağrısı özelliklerine dikkat etmeliler ve baş ağrısının erken COVID-19 enfeksiyon göstergesi olabileceğini akıllarında tutmalılardır.
Headache is the most common neurological symptom associated with COVID-19. We aimed to reveal the diagnostic clues of headache for COVID-19 infection and to investigate the course of primary headaches during the pandemic. Method: Our study was carried out by telemedicine searching the cases who were hospitalized in our hospital between December 2020 and June 2021 and were diagnosed with COVID-19 based on the current Ministry of Health COVID-19 guide. As the patient group, 102 patients between the ages of 18-95 who were diagnosed with COVID-19 and had a headache during their illness, and 96 patients between the ages of 18-95 who were diagnosed with COVID-19 and had no headache during the disease were included in the study as the control group. A standardized questionnaire was used for data collection. Results: In our study, 102 (51.5%) of 198 subjects (Patient: 102, Control: 96) were male and 96 (48.5%) were female. The mean age of the headache group was 56.48±14.73, and the mean age of the control group was 57.81±15.89 years. There was no significant difference between headache and control groups in terms of gender and age (p>0.05). Weight loss was detected in 102 (51.5%) cases, taste loss in 85 (42.9%) cases, and smell loss in 84 (42.4%) cases. Considering the degree of taste loss, 50 (25.3%) of the patients had complete taste loss, while 113 (57.1%) had no taste loss. Considering the degree of olfactory loss, 50 (25.3%) of the patients had complete loss of smell, while 114 (57.6%) had no loss of smell. Weight loss, loss of taste, loss of smell, degree of loss of smell and vii severity of infection were found to be significantly higher in the headache group (p<0.05). There was no significant difference between the groups in terms of the degree of taste loss (p>0.05). In our study, weight loss and gender were found to be independent risk factors in the headache group. Weight loss, gender and taste loss were found to be independent variables in individuals with olfactory loss. Among the laboratory values, D-dimer and fibrinogen were found to be significantly higher in the headache group (p<0.05). When examined in terms of comorbidities, the number of patients with respiratory pathology in the headache group was found to be significantly higher (p<0.05). In the headache group, the frequency of additional headaches and an increase in headache with COVID-19 were found to be significantly higher (p<0.05). According to localization, 23 (22.5%) of the patients were in the frontal region, 33 (32.4%) in the temporal region, 17 (16.7%) in the parietal region, 58 (56.9%) in the occipital region. headache was present. There was diffuse headache in 23 (22.5%), bilateral headache in 10 (9.8%), and unilateral headache in 9 (8.8%) patients. When we look at the headache feature, it was throbbing in 74 (72.5%) and compressive in 22 (21.6%). The median of the NRS (Numeric Rating Scale) score used in the assessment of headache severity in our patients was 7 (IQR 3). There was no relationship between headache and fever in 76 (74.5%) of our patients. In 70 (68.6%), there was no relationship between headache and cough. Nausea and vomiting were not accompanied by 86 (84.3%). All 83 (81.4%) had no sensitivity to light and sound at the time of their headaches. 79 (77.5%) responded moderately to painkillers. It was determined that headache did not change with physical activity in 57 (55.9%) of them. Conclusion: Headache is a very common symptom of COVID-19. Clinicians following patients with COVID-19 infection should pay attention to the headache characteristics that may be seen in these patients and should keep in mind that headache may be an early indicator of COVID-19 infection.
Headache is the most common neurological symptom associated with COVID-19. We aimed to reveal the diagnostic clues of headache for COVID-19 infection and to investigate the course of primary headaches during the pandemic. Method: Our study was carried out by telemedicine searching the cases who were hospitalized in our hospital between December 2020 and June 2021 and were diagnosed with COVID-19 based on the current Ministry of Health COVID-19 guide. As the patient group, 102 patients between the ages of 18-95 who were diagnosed with COVID-19 and had a headache during their illness, and 96 patients between the ages of 18-95 who were diagnosed with COVID-19 and had no headache during the disease were included in the study as the control group. A standardized questionnaire was used for data collection. Results: In our study, 102 (51.5%) of 198 subjects (Patient: 102, Control: 96) were male and 96 (48.5%) were female. The mean age of the headache group was 56.48±14.73, and the mean age of the control group was 57.81±15.89 years. There was no significant difference between headache and control groups in terms of gender and age (p>0.05). Weight loss was detected in 102 (51.5%) cases, taste loss in 85 (42.9%) cases, and smell loss in 84 (42.4%) cases. Considering the degree of taste loss, 50 (25.3%) of the patients had complete taste loss, while 113 (57.1%) had no taste loss. Considering the degree of olfactory loss, 50 (25.3%) of the patients had complete loss of smell, while 114 (57.6%) had no loss of smell. Weight loss, loss of taste, loss of smell, degree of loss of smell and vii severity of infection were found to be significantly higher in the headache group (p<0.05). There was no significant difference between the groups in terms of the degree of taste loss (p>0.05). In our study, weight loss and gender were found to be independent risk factors in the headache group. Weight loss, gender and taste loss were found to be independent variables in individuals with olfactory loss. Among the laboratory values, D-dimer and fibrinogen were found to be significantly higher in the headache group (p<0.05). When examined in terms of comorbidities, the number of patients with respiratory pathology in the headache group was found to be significantly higher (p<0.05). In the headache group, the frequency of additional headaches and an increase in headache with COVID-19 were found to be significantly higher (p<0.05). According to localization, 23 (22.5%) of the patients were in the frontal region, 33 (32.4%) in the temporal region, 17 (16.7%) in the parietal region, 58 (56.9%) in the occipital region. headache was present. There was diffuse headache in 23 (22.5%), bilateral headache in 10 (9.8%), and unilateral headache in 9 (8.8%) patients. When we look at the headache feature, it was throbbing in 74 (72.5%) and compressive in 22 (21.6%). The median of the NRS (Numeric Rating Scale) score used in the assessment of headache severity in our patients was 7 (IQR 3). There was no relationship between headache and fever in 76 (74.5%) of our patients. In 70 (68.6%), there was no relationship between headache and cough. Nausea and vomiting were not accompanied by 86 (84.3%). All 83 (81.4%) had no sensitivity to light and sound at the time of their headaches. 79 (77.5%) responded moderately to painkillers. It was determined that headache did not change with physical activity in 57 (55.9%) of them. Conclusion: Headache is a very common symptom of COVID-19. Clinicians following patients with COVID-19 infection should pay attention to the headache characteristics that may be seen in these patients and should keep in mind that headache may be an early indicator of COVID-19 infection.
Açıklama
Anahtar Kelimeler
COVID-19, SARS-CoV-2, Nörolojik semptomlar, Baş ağrısı, COVID-19, SARS-CoV-2, Headache, Neurological symptoms
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Dağlı, Ç. (2022). COVID-19 enfeksiyonu geçiren hastalarda baş ağrısı özellikleri ve risk faktörleri. (Yayınlanmamış tıpta uzmanlık tezi) Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi Cerrahi Tıp Bilimleri Bölümü Anesteziyoloji ve Reanimasyon Anabilim Dalı, Konya.
